Trials / Recruiting
RecruitingNCT06783127
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,000 (estimated)
- Sponsor
- Santa Chiara Hospital · Academic / Other
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaparib | Olaparib given according the clinical practice to BRCA positive mCRPC patients |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2025-01-20
- Last updated
- 2025-02-11
Locations
2 sites across 1 country: Italy
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06783127. Inclusion in this directory is not an endorsement.